TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00827112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
Study: NCT03955003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Drumming
Description: Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Attention Control
Description: This is intended to control for time, place, and group affect.
Study: NCT03507959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLP scientifically-objective
Description: Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
Study: NCT00827112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
Study: NCT01197976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEPSO cloth
Description: TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
Study: NCT03507959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLP personally-affective
Description: Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DP scientifically-objective
Description: Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DP personally-affective
Description: Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
Study: NCT01399632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Fat and High Carbohydrate Diet
Description: Low Fat and High Carbohydrate Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Fat and Low Carbohydrate Diet
Description: High Fat and Low Carbohydrate Diet
Study: NCT01197976

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard cloth
Description: Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
Study: NCT02120703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregablin 75 mg per oral two times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 200 mg twice daily per oral
Study: NCT03821272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PepCan
Description: 50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
Study: NCT03347279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT04187560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB-102
Description: (N-Methyl amisulpride)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB-102
Description: (N-Methyl amisulpride)
Study: NCT05542472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Support Program Based on a Nurse-Led Case Management Model
Description: A Family Support Program Based on the Nurse-Led Case Management Model create for the care givers in the intervention group. Case management is the process of planning an individual's care, coordinating it, managing it, implementing it and reviewing it. The aim in case management is to improve a person's quality of life by coordinating health care services and providing these services at a reasonable cost and in a productive way. The use of case management requires the cooperation of professionals from many different disciplines. Therefore, in areas where case management is applied, the case manager coordinates an individual's or patient's care by enabling this cooperation. In this way, in areas where health services are provided, the case manager may be a doctor, a nurse, a physiotherapist, a social services expert, or a speech therapist.
Study: NCT04187560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB-102
Description: (N-Methyl amisulpride)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB-102
Description: (N-Methyl amisulpride)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB-102
Description: (N-Methyl amisulpride)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB-102
Description: (N-Methyl amisulpride)
Study: NCT03264027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Description: Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambient air
Description: Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Argon fulguration
Description: The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argon fulguration
Description: The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
Study: NCT01741584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stationary bike exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aerobic
Study: NCT02430675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT00311623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin 3mg
Description: Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
Study: NCT04343612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes
Study: NCT02530281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium Topical Wipes
Description: Topical wipes containing glycopyrronium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle (placebo) topical wipes
Study: NCT03855358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 Injection and Anlotinib Hydrochioride Capsules
Description: TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT04815915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston technique
Description: Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
Study: NCT00963469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast 10 mg tablet orally once daily in the morning for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: loratadine
Description: loratadine 10 mg tablet orally once daily in the morning for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo tablet orally once daily in the morning for 4 weeks
Study: NCT01435564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone
Description: Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
Study: NCT03821272

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline solution per dose administered intradermally in the extremities
Study: NCT01292564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia MLS
Description: The Erchonia MLS emits 635 nm low level laser light.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
Study: NCT06339138

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT01952990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: 1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
Study: NCT01159236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 500 mg/m2 for 4 courses (once every 7 days)
Study: NCT00311623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin 6mg
Description: Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy
Description: Radical prostatectomy performed on Day 15
Study: NCT01159236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
Study: NCT02624193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR Program
Description: Mindfulness-based stress reduction, as described previously.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HT Program
Description: Health education curriculum, as described previously
Study: NCT02248207

Intervention type: DRUG
Intervention: Pramipexole
Study: NCT01159236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
Study: NCT05063266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Breathing Exercise
Description: control groups received deep breathing exercise 6 days a week for two weeks. Deep breathing exercises includes diaphragmatic breathing and pursed lip breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle Training
Description: Treatment group received inspiratory muscle training 20 minutes 6 days a week for two weeks.IMT was done by using pressure threshold device.
Study: NCT00316693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine (Cervarix™)
Description: Intramuscular injection, 3 doses
Study: NCT00311623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: Radical prostatectomy performed on Day 15

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: Radical prostatectomy performed on Day 15
Study: NCT00469092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
Study: NCT00316693

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aimmugen™
Description: Intramuscular injection, 3 doses
Study: NCT00871039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients to be sedated for up to 72 hours with study drug propofol
Study: NCT00469092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 2550 mcg. Administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 2550 mcg. Administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: Tablets 2 mg. 4, 6 or 8 mg administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets 2 mg. 4, 6 or 8 mg administered once daily.
Study: NCT02364544

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relapse Prevention Plan
Description: brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
Study: NCT01435564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pedometer only
Description: Participants in this group will receive only a pedometer.
Study: NCT01204489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified dietary counseling at child wellfare clinics.
Description: The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensified dietary counseling at child wellfare clinics.
Description: The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
Study: NCT02364544

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily Support Website
Description: web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer CBT for voices and paranoia
Description: A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FOCUS
Description: an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia

Intervention type: OTHER
Group type: OTHER
Intervention: Prescriber Decision Assistant
Description: is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
Study: NCT00871039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients to be sedated for up to 72 hours with study drug midazolam
Study: NCT04008992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Single and Multiple ascending dose from Dose 1 to Dose 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259
Study: NCT01924260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Given IV
Study: NCT01719627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Unique dose of Maraviroc 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TVD 300/200 QD
Description: TVD 300/200 QD during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Unique dose of Maraviroc 600mg
Study: NCT04234282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Physical Therapy
Description: Orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment.
Study: NCT02150954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitocin
Study: NCT04375137

Intervention type: DIAGNOSTIC_TEST
Intervention: Oxidative Stress ELISA Kit
Description: Checking oxidative stress markers and redox system status

Intervention type: DIAGNOSTIC_TEST
Intervention: Oxidative Stress ELISA Kit
Description: Checking oxidative stress markers and redox system status

Intervention type: DIAGNOSTIC_TEST
Intervention: Oxidative Stress ELISA Kit
Description: Checking oxidative stress markers and redox system status
Study: NCT00390533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saredutant
Description: oral administration (capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saredutant
Description: oral administration (capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration (capsules)